06:35:19 EDT Fri 29 Mar 2024
Enter Symbol
or Name
USA
CA



Bright Minds Biosciences Inc
Symbol DRUG
Shares Issued 11,771,361
Close 2022-08-30 C$ 2.93
Market Cap C$ 34,490,088
Recent Sedar Documents

Bright Minds doses 1st patient in BMB-101 phase 1 trial

2022-08-31 09:05 ET - News Release

Mr. Ian McDonald reports

BRIGHT MINDS BIOSCIENCES INITIATES DOSING IN PHASE I CLINICAL TRIAL OF BMB-101 FOR DRAVET SYNDROME

Bright Minds Biosciences Inc. has dosed the first patient in a phase I trial (NCT 05397041) for its lead product, BMB-101, for the treatment of Dravet syndrome and other medical indications. The phase I trial is being conducted in Adelaide, Australia, by CMAX Clinical Research, a clinical trial centre specializing in a range of early-phase trials and first-time in-human studies.

BMB-101, a next-generation, 5-HT2C selective and biased agonist, exhibits compelling behavioural and preclinical pharmacology and safety data with the potential to be the best-in-class drug. In well-established, predictive animal models, BMB-101 demonstrated a significant reduction in both the number and intensity of epileptic seizures.

"BMB-101 was designed with the aim of improving the safety profile relative to earlier medications in this class, and we are excited about the potential to deliver an improved therapeutic to address this rare and devastating disease. Based on the strength of BMB-101's preclinical data and encouraging scientific rationale of 5-HT2C agonism in the treatment of Dravet syndrome, we are enthusiastic to advance our lead product into clinical trials," stated Dr. Revati Shreeniwas, chief medical officer of Bright Minds Biosciences.

The phase I clinical trial is a three-part (single ascending dose, food effects, multiple ascending dose) randomized, placebo-controlled study of BMB-101 in approximately 76 healthy volunteers, that is being conducted in Australia. The trial aims to evaluate the safety, tolerability and other pharmacokinetics of BMB-101 for use in phase II clinical trials.

"Dosing the initial subject in the first-in-human trial of BMB-101 is an exciting milestone for Bright Minds. After several years of discovery and early development of next-generation, best-in-class serotonergic investigational drugs, we are delighted to progress into human trials. We are hopeful that our efforts result in more efficacious and safer drugs for patients suffering from Dravet syndrome, which remains an area of high unmet medical need," stated Ian McDonald, chief executive officer and co-founder of Bright Minds Biosciences.

About BMB-101

BMB-101, a 5-HT2C selective and biased agonist, has demonstrated compelling activity in a host of in vitro and in vivo non-clinical tests. Compared with locaserin, BMB-101 exhibits strong Gq signalling coupled with minimal beta-arrestin recruitment. Mechanistically, serotonin (5-hydroxytryptamine, 5-HT) is a monoamine neurotransmitter widely expressed in the central nervous system, and drugs modulating 5-HT have made a major impact in mental health disorders. Central 5-HT systems have long been associated with the control of ingestive behaviour and the modulation of behavioural effects of psychostimulants, opioids, alcohol and nicotine. Over the past decade, the various 5-HT receptor subtypes have been cloned and characterized. Results of clinical trials and animal studies indicate that 5-HT2C up receptor agonists may have therapeutic potential in the treatment of addiction by decreasing the intake of opioids as well as impulsive behaviour that can escalate compulsive drug use.

About Dravet syndrome

Dravet syndrome is an epilepsy syndrome that begins in infancy or early childhood and can include a spectrum of symptoms ranging from mild to severe. Children with Dravet syndrome exhibit focal (confined to one area) or generalized (throughout the brain) convulsive seizures that start before 15 months of age (often before age one). These initial seizures are often prolonged and involve half of the body, with subsequent seizures that may switch to the other side of the body. These initial seizures are frequently associated with fever. Other seizure types emerge after 12 months of age and can be quite varied. Status epilepticus -- a state of continuous seizure requiring emergency medical care -- may occur frequently in these children, particularly in the first five years of life. Dravet syndrome affects an estimated 1:15,700 individuals in the United States, or 0.0064 per cent of the population (Wu, 2015). Approximately 80 to 90 per cent of those, or 1:20,900 individuals, have both an SCN1A mutation and a clinical diagnosis of DS. This represents an estimated 0.17 per cent of all epilepsies. As an area of high, unmet medical need, there currently exist only three Food and Drug Administration-approved medications for the treatment of DS: (1) Fintepla (fenfluramine), which has a black-box label; (2) Diacomit (stiripentol) and Epidolex (cannabidiol).

About Bright Minds Biosciences Inc.

Bright Minds is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy and pain. Bright Minds has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, posttraumatic stress disorder and pain. The company leverages its world-class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs. Bright Minds' drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating potentially superior drugs to first-generation compounds, such as psilocybin.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.